Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo, Ranbaxy To Launch Olmesartan In Six African Countries

This article was originally published in PharmAsia News

Executive Summary

TOKYO - In what is being called the first formidable entry into the African market by a leading pharmaceutical group, Daiichi Sankyo and its Indian generic subsidiary Ranbaxy announced Dec. 22 they will jointly launch Daiichi's proprietary hypertension treatment Olvance (olmesartan) in the six countries of Kenya, Mozambique, Nigeria, Tanzania, Uganda and Zambia

You may also be interested in...



Daiichi Sankyo Acquires U.S. Generic Injectables Maker PharmaForce

TOKYO - Daiichi Sankyo's U.S. subsidiary, Luitpold Pharmaceutical of New York has fully acquired PharmaForce of Columbus, Ohio, a specialty injectable pharmaceutical company, the Tokyo-based company said

Daiichi Sankyo Acquires U.S. Generic Injectables Maker PharmaForce

TOKYO - Daiichi Sankyo's U.S. subsidiary, Luitpold Pharmaceutical of New York has fully acquired PharmaForce of Columbus, Ohio, a specialty injectable pharmaceutical company, the Tokyo-based company said

Daiichi Sankyo, Ranbaxy To Start Joint Marketing In Mexico, Romania

TOKYO - Dust from their merger settled, Daiichi Sankyo and generics manufacturing Indian subsidiary Ranbaxy are flexing their muscles, readying to start marketing brand and generic pharmaceuticals in Mexico and launching the postmenopausal osteoporosis drug Evista in Romania

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel